Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106).

Hiroki YukamiHiasto KawakamiToshifumi YamaguchiDaisuke SakaiToshio ShimokawaYukinori KurokawaMasahiro GotoTaroh Satoh

Published in: International journal of clinical oncology (2023)

The potential treatment efficacy of this triplet regimen in HER2-negative advanced gastric cancer warrants further evaluation, especially in patients requiring intensive chemotherapy.

Keyphrases

end stage renal disease
neoadjuvant chemotherapy
locally advanced
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
squamous cell carcinoma
clinical trial
lymph node
patient reported outcomes
climate change
rectal cancer
chemotherapy induced
study protocol